Welcome to our dedicated page for Cbdmd news (Ticker: YCBD), a resource for investors and traders seeking the latest updates and insights on Cbdmd stock.
cbdMD, Inc. (NYSE American: YCBD) generates a steady flow of corporate, financial, and strategic news tied to its position in the hemp-derived wellness and cannabinoid products space. Company press releases and SEC filings highlight developments across its cbdMD and Paw CBD brands, ATRx Labs functional mushroom products, and Herbal Oasis hemp-derived THC social seltzers, as well as capital markets activity and exchange-listing matters.
News for YCBD often covers operating performance, including updates on net sales, gross profit, and operating loss trends disclosed in conjunction with annual and quarterly results. The company has reported multiple years of operating improvement and has discussed cost management, product portfolio optimization, and marketing investments in its communications. Investors following YCBD news also see disclosures about preferred stock financings, such as Series B and Series C Convertible Preferred Stock, and the establishment of an equity line of credit registered on Form S-1.
Regulatory and listing-related announcements form another key part of cbdMD’s news flow. The company has reported regaining full compliance with NYSE American continued listing standards after addressing equity-related deficiencies, and it has furnished related information through Form 8-K filings. Policy commentary around federal discussions on cannabinoids and hemp-derived products, and how those discussions may affect research and investment in the category, also appears in its releases.
Strategic updates, including the asset acquisition of Gaia Botanicals, LLC and its Bluebird Botanicals brand and online CBD marketplace, are disclosed through press releases and 8-K filings. These items provide detail on how cbdMD is expanding its brand portfolio, intellectual property base, and product offerings in CBD and related categories. For investors and observers, the YCBD news page offers a centralized view of earnings communications, capital transactions, regulatory milestones, and brand-level initiatives across cbdMD’s wellness platform.
cbdMD (NYSE American: YCBD) has received a noncompliance notice from NYSE American, indicating that the company does not meet the continued listing standards. As of March 31, 2024, the company reported stockholders' equity of $3.1 million, below the required $4 million. Additionally, it has reported losses in three of the last four fiscal years. cbdMD must submit a compliance plan by July 5, 2024, to regain compliance by December 5, 2025. Although the notice does not affect the company's immediate operations or trading status, the stocks will carry a "BC" designation for being below compliance. cbdMD aims to achieve profitability and has announced cost reductions to be implemented by August 2024. The company is also considering converting Preferred Stock liabilities to equity to meet compliance but is not assured of success.
cbdMD (NYSE American: YCBD) has launched the ATRx Labs Premium Mushroom Line exclusively at GNC stores nationwide. The line consists of four products targeting various health needs: Energy & Stamina, Memory & Cognition, Digestion & Microbiome, and Immune Support. Each supplement merges powerful mushroom extracts with clinically studied ingredients to support natural wellness. This strategic partnership with GNC aims to meet the increasing consumer demand for natural health solutions, marking cbdMD's expansion in the wellness sector beyond CBD products.
On May 16, 2024, cbdMD announced its new Max Chill Dragon Fruit D9 Gummies, featuring a 1:1 CBD to THC ratio. Each gummy contains 10mg of Delta 9 THC and 10mg of CBD, aiming to provide balanced relaxation and stress relief. The gummies are vegan, gluten-free, and have a tropical dragon fruit flavor. Priced at $39.99, they are available on cbdMD's website.
cbdMD reported its financial results for Q2 of fiscal 2024, showing a slight increase in operational losses from $1.4 million to $1.5 million YoY. Net sales decreased by 30% to $4.4 million, with DTC sales dropping 26% and wholesale sales falling 44%. Despite these setbacks, the company launched its ATRx Platinum line in GNC stores, aiming to expand market presence. Cost-cutting measures are projected to save $2.4 million annually, potentially leading to positive cash flow by August. The company also closed $1.25 million in net financing through convertible notes. Net loss for the quarter was $4 million, or $1.35 per share, attributable to a non-cash contingency liability.
cbdMD, Inc. will host a conference call on May 15, 2024, to discuss their second-quarter fiscal 2024 financial results and business progress. The company is a prominent CBD company with a strong reputation. The call will take place at 4:20 p.m. Eastern Time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.